<DOC>
	<DOCNO>NCT00559936</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety Topical Bevacizumab ( Avastin ) treatment corneal neovascularization .</brief_summary>
	<brief_title>Topical Avastin Treatment Corneal Neovascularization</brief_title>
	<detailed_description>Primary outcome measure include neovascular area ( NA ) , define area corneal vessel ; vessel caliber ( VC ) , define mean diameter corneal vessel ; invasion area ( IA ) , define fraction total cornea vessel extend . The occurrence ocular systemic adverse event closely monitor throughout course study .</detailed_description>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Male female , least 18 year age Clinical stable corneal neovascularization ( define ) Ability understand provide inform consent participate study willingness follow study instruction likely complete require visit . All female patient childbearing potential exclude . A female consider childbearing potential unless postmenopausal without menses 12 month without uterus and/or ovary . Current recent ( ≤ 1 month ) systemic corticosteroid therapy periocular corticosteroid injection study eye Current recent ( ≤ 3 month ) intravitreal drug injection study eye ; recent ( ≤ 1 month ) change dose frequency topical steroid and/or nonsteroidal antiinflammatory agent Uncontrolled hypertension define systolic blood pressure ≥ 150 mmHg diastolic blood pressure ≥ 90 mmHg ; history thromboembolic event , include myocardial infarction cerebral vascular accident Patients age 75 old ; history renal abnormality Recent ( ≤ 3 month ) plan surgery History coagulation abnormality , include end stage liver disease current anticoagulation medication aspirin ( warfarin , heparin , enoxaparin , similar anticoagulant agent ) All female patient childbearing potential ( female consider childbearing potential unless postmenopausal without menses 12 month without uterus and/or ovary ) Any condition ( include language barrier ) preclude patient 's ability comply study requirement include completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>